Federal contractor · LONG BEACH, CA

ANIVIVE LIFESCIENCES INC

No contract obligations recorded for ANIVIVE LIFESCIENCES INC in FY2026. Since FY2024: $4.9M. Its largest customer was National Institutes of Health ($0).

Obligations · FY2026: $0
New awards: 1
Sole-source: —
Single offer: —

UEI: HR9KVMTD5467

Small business

Open in the contracts explorer Relationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

4.9MFY2024
0FY2026

Top buying agencies

Obligations in FY2026.

National Institutes of Health$00.0%
1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

BAA RESEARCH AREA 001 - DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES$4.9M
National Institutes of Health· Los Angeles County, CA· Research & development· Jun 3, 2024 – Jul 7, 2026· 75N93024C00009

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

ANIVIVE LIFESCIENCES INC received -$64.4K in federal assistance in FY2026, on 2 actions (0 new awards). Its largest program was 93.103 · Food and Drug Administration Research (-$64.4K).

Assistance · FY2026: -$64.4K
New awards: 0
Actions: 2
Since FY2021: $278.5K

Assistance by fiscal year

250KFY2021
250KFY2023
-157.2KFY2024
-64.4KFY2026

By type

Grants-$64.4K0.0%

Top programs

93.103 · Food and Drug Administration Research-$64.4K0.0%

Largest awards

COMPARABILITY PROTOCOL FOR 22.5 MG TABLETS (NADA # 141-526) - PROJECT SUMMARY/ABSTRACT THE PROTOCOL IS TO ADD AN ADDITIONAL STRENGTH OF…$28.5K
93.103 · Food and Drug Administration Research· Food and Drug Administration· Project grant· Dec 7, 2022 – Aug 4, 2026· R01FD007800

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2021–FY2026.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

EVELIQURE BIOTECHNOLOGIES GMBH$4.9M−100% in FY2026
WIEN, AUT · 99.8% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
MOLECULAR EXPRESS, INC$5M
RANCHO DOMINGUEZ, CA · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
VERSATOPE THERAPEUTICS INC$4.6M−100% in FY2026
LOWELL, MA · 93% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026 · FY2024–FY2026.

Lobbying and PAC activity

Organizations in House lobbying disclosures and FEC records whose names an AI judgment matched to this company. Those records carry no identifier shared with contracts, so every match is by name.

Matched organizations

Anivive Lifesciences Inc.AI match · 100%

Lobbying · 2024: $210K; 7 reports
Lobbying · 2023–2024: $410K

Lobbying by year

2023$200K
3 reports
2024$210K
7 reports

Top issues

Health issues7 reports
Agriculture2 reports
Medical and disease research, clinical labs2 reports

Who was contacted

U.S. HOUSE OF REPRESENTATIVES7 reports
U.S. SENATE7 reports

Houses of Congress and federal agencies the reports list as contacted (a report names every one for all its issues).

Lobbying firms hired

JEFFREY J. KIMBELL & ASSOCIATES, INC.$300K
5 reports
Tiber Creek Group$110K
5 reports

Registrants who are individuals are counted, not named.

Lobbying amounts are the filers' own good-faith estimates on quarterly LD-2 reports (the law asks for amounts rounded to $10,000; under $5,000 need not be itemized), latest amendment only. When an organization files its own report, it replaces what outside firms report for it that quarter. Matches are by name. Lobbying and political giving are legal and public: they show engagement with government, not influence over any award. Correlation is not influence: these organizations' lobbying and their contracts are shown side by side, and nothing here implies either affected the other.

Source: Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives), data current to Oct 10, 2026, loaded Oct 10, 2026 · 2023–2026.

Source: Committees, candidates and committee contributions to candidates (Federal Election Commission), data current to Oct 10, 2026, loaded Oct 10, 2026 · 2026, 2024, 2022.

Matches: Analisa AI name judgments (entity-match@1), updated Oct 5, 2026.

Congress: members and bills

Through the organizations matched to this company: members of Congress whose campaigns received contributions from their PACs, and the bills their lobbying reports named. Shown beside the company's contracts as a comparison, not a cause.

Bills named in its lobbying reports

H.R. 6227 · Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 20232 reports
118th Congress · Introduced · 2023–2024
H.R. 6731 · FORWARD Act of 20232 reports
118th Congress · Introduced · 2023–2024
S. 3220 · A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.2 reports
118th Congress · Introduced · 2023–2024
S. 3464 · FORWARD Act of 20232 reports
118th Congress · Introduced · 2023–2024

2 of 10 reports (2023–2024) name at least one bill. Bills and resolutions the current reports name in their issue descriptions, by number of reports. A report names what it lobbied on, not which side it took.

Amounts, members and bills are as recorded, shown side by side. They say nothing about why a contribution was made, how a member voted or what a report sought. A bill number written in a report is read as the measure of the Congress its context points to (a law's number, the Congress written next to it, the title), else of the Congress then sitting.

Source: Committees, candidates and committee contributions to candidates (Federal Election Commission), data current to Oct 10, 2026, loaded Oct 10, 2026.

Source: Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives), data current to Oct 10, 2026, loaded Oct 10, 2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 10, 2026, loaded Oct 10, 2026.